Jill Feldman (@jillfeldman4), lung cancer survivor and advocate, shares her familial history of lung cancer that drove her to advocacy work long before her own diagnosis of EGFR-positive disease, as well as her treatment courses with erlotinib and subsequent SBRT for many years before osimertinib. Jill then describes her “journey” in advocacy, beginning with self-advocacy and the LUNGevity Foundation, independent research advocacy and representing lung cancer patients, and co-founding the EGFR Resisters (@EGFRResisters) – a group of EGFR-positive patients who are resistant to targeted treatment. Her message for clinicians and scientists is to start thinking of patients as partners in research.